Management of Metastatic Anal Cancer with Solitary Liver Metastasis

First‑Line Systemic Therapy

The NCCN recommends carboplatin + paclitaxel as the preferred first‑line regimen for chemotherapy‑naïve metastatic anal cancer, based on the InterAACT phase III trial that showed a median overall survival of 20 months versus 12.3 months with cisplatin/5‑FU and a more favorable toxicity profile. 3
Carboplatin + paclitaxel achieved a 59 % objective response rate, with serious adverse events occurring in 36 % of patients compared with 62 % for cisplatin/5‑FU (P = 0.016). 1
The hazard ratio for overall survival favored carboplatin + paclitaxel at 2.0 (95 % CI 1.15‑3.47; P = 0.014). 3

FOLFCIS (5‑FU, leucovorin, cisplatin) demonstrated a 48 % response rate and a median overall survival of 22.1 months in a retrospective series, offering a viable alternative when carboplatin + paclitaxel is unsuitable. 1
FOLFOX (5‑FU, leucovorin, oxaliplatin) is considered a safe alternative with documented efficacy, though specific outcome metrics were not reported. 1
Modified DCF (docetaxel, cisplatin, 5‑FU) receives a Category 2B NCCN recommendation; phase II data indicate encouraging activity in metastatic anal cancer. 3
Cisplatin + 5‑FU also carries a Category 2B recommendation; it provides comparable efficacy to carboplatin + paclitaxel but is associated with higher toxicity. 1

After achieving disease control with systemic therapy, a solitary 3‑cm liver metastasis may be amenable to surgical resection or ablative techniques. 1
A retrospective analysis of 106 patients showed that resection or ablation of liver metastases can lead to long‑term survival, with patients whose primary tumor is anal cancer experiencing better outcomes than those with other squamous cell carcinomas. 1
Although not yet incorporated into the NCCN Guidelines, liver‑directed therapy is considered a reasonable option for carefully selected patients who have a solitary, resectable lesion and demonstrate a good response to initial chemotherapy. 1

Initiate carboplatin + paclitaxel as first‑line systemic therapy. 1
Re‑evaluate after 2–3 cycles with cross‑sectional imaging to assess tumor response and resectability of the liver lesion. 1
If a good response is observed and the liver metastasis remains solitary and resectable, refer the patient for multidisciplinary discussion regarding surgical resection or ablation. 1
Continue systemic therapy for a total of 4–6 cycles when pursuing a non‑surgical approach, or administer peri‑operative chemotherapy when resection is planned. 1

Palliative chemoradiotherapy to the primary anal tumor may be employed after upfront chemotherapy when bulky, symptomatic disease requires local control. 1
National Cancer Database data indicate that patients with newly diagnosed metastatic anal cancer who receive definitive pelvic radiotherapy combined with chemotherapy have a longer median overall survival than those treated with chemotherapy alone (21.3 months vs 15.9 months; HR 0.70; P < 0.001). 1

The overall 5‑year relative survival for metastatic anal cancer is approximately 30 %. 3
Median overall survival with carboplatin + paclitaxel is 20 months; patients with solitary, resectable liver metastases may experience extended survival beyond this benchmark. 1